
Otsuka and GW Pharmaceutical’s multiple sclerosis drug Sativex has failed to meet the primary endpoint in its first Phase III …
Pharmafocus presents a round-up of developments in manufacturing, including facility updates from GW and Viva Biopharm, GMP problems at an …
Sativex, the cannabis-derived product developed by GW Pharmaceuticals, could be finally set for European approval after five years of delay. …
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact

